Pyrimidine compounds and methods of making and using same
View Patent ↗Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.
1. A compound represented by Formula I:
or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
R 1 is —O—(CR 6 R 7 ) n -A 2 , —N(R 6 )(CR 6 R 7 ) n -A 2 , —S—(CR 6 R 7 ) n -A 2 , or heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 6 alkoxyl, hydroxyl, —CF 3 , —CH 2 F, —CHF 2 , —N(R 8 )R 9 , —CN, —C(O)R 10 , —CO 2 R 8 , —OC(O)R 9 , —CON(R 8 )R 9 , —N(R 8 )COR 10 , —N(R 8 )SO 2 R 10 , —SO 2 N(R 8 )R 9 , —N(R 8 )SO 2 N(R 8 )R 9 , and —SO 2 R 10 ;
R 2 is —O-heterocycloalkyl, —O-heterocycloalkenyl, —Y-heterocycloalkyl, —Y-heterocycloalkenyl, heterocycloalkyl, -heterocycloalkenyl, -cycloalkyl, -cycloalkenyl, —(CR 6 R 7 ) n —C 1 -C 6 alkoxyl, —O—(CR 6 R 7 ) n —C 1 -C 6 alkoxyl, C 1 -C 6 alkoxyl, halogen, —CF 3 , —CH 2 F, —CHF 2 , —OCF 3 , —OCH 2 F, hydroxyl, or C 1 -C 6 alkyl, wherein said heterocycloalkyl, heterocycloalkenyl, cycloalkyl, and cycloalkenyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 6 alkoxyl, hydroxyl, —CF 3 , —CH 2 F, —CHF 2 , —OCF 3 , —N(R 8 )R 9 , —CN, —C(O)R 10 , —CO 2 R 8 , —OC(O)R 9 , —CON(R 8 )R 9 , —N(R 8 )COR 10 , —N(R 8 )SO 2 R 10 , —SO 2 N(R 8 )R 9 , —N(R 8 )SO 2 N(R 8 )R 9 , and —SO 2 R 10 ;
R 3 is hydrogen, halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 6 alkoxyl, hydroxyl, —CF 3 , —CH 2 F, —CHF 2 , —OCF 3 , —OCH 2 F, —N(R 8 )R 9 , —CN, —C(O)R 10 , —CO 2 R 8 , —CON(R 8 )R 9 , —N(R 8 )COR 10 , —N(R 8 )SO 2 R 10 , —SO 2 N(R 8 )R 9 , or —SO 2 R 10 ;
R 4 is hydrogen, halogen, C 1 -C 4 alkyl, cyclopropyl, —CN, or —CF 3 ;
R 5 is hydrogen or C 1 -C 4 alkyl;
R 6 and R 7 each represent independently for each occurrence hydrogen or alkyl, or when R 6 and R 7 are attached to the same atom, R 6 and R 7 are optionally taken together with the atom to which they are attached to form a 3-6 membered cycloalkyl or heterocycloalkyl group;
R 8 and R 9 each represent independently for each occurrence hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; or when R 8 and R 9 are attached to the same atom, R 8 and R 9 are optionally taken together with the atom to which they are attached to form a 3-6 membered cycloalkyl or heterocycloalkyl group;
R 10 represents independently for each occurrence alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;
A 1 is phenylene or a monocyclic heteroarylene group;
A 2 is a heterocycloalkyl group containing at least one nitrogen or sulfur atom, and wherein said heterocycloalkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 6 alkoxyl, C 3 -C 6 cycloalkyl, hydroxyl, —CF 3 , —CH 2 F, —CHF 2 , —N(R 8 )R 9 , —CN, —C(O)R 10 , —CO 2 R 8 , —OC(O)R 9 , —CON(R 8 )R 9 , —N(R 8 )COR 10 , —N(R 8 )SO 2 R 10 , —SO 2 N(R 8 )R 9 , —N(R 8 )SO 2 N(R 8 )R 9 , and —SO 2 R 10 ;
W is C 1 -C 6 alkyl or C 4 -C 10 cycloalkyl, each of which are optionally substituted with one, two, or three substituents independently selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, —OC 1 -C 6 alkyl, —O-cycloalkyl, —OH, —CF 3 , and fluoro;
Y is —N(R 8 )—, —S—, —S(O)—, or —S(O) 2 —;
m is 1 or 2; and
n is 0, 1, 2, 3, or 4.
2. The compound of claim 1 , wherein R 1 is —O—(CR 6 R 7 ) n -A 2 or a heterocycloalkyl group optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —C(O)R 10 , —CO 2 R 8 , —OC(O)R 9 , —CON(R 8 )R 9 , —N(R 8 )COR 10 , —N(R 8 )SO 2 R 10 , —SO 2 N(R 8 )R 9 , —N(R 8 )SO 2 N(R 8 )R 9 , and —SO 2 R 10 .
3. The compound of claim 1 , wherein R 1 is —O—(CR 6 R 7 ) n -A 2 .
4. The compound of claim 3 , wherein A 2 is a heterocycloalkyl group containing at least one nitrogen or sulfur atom, and wherein said heterocycloalkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —C(O)R 10 , —CO 2 R 8 , —OC(O)R 9 , —CON(R 8 )R 9 , —N(R 8 )COR 10 , —N(R 8 )SO 2 R 10 , —SO 2 N(R 8 )R 9 , —N(R 8 )SO 2 N(R 8 )R 9 , and —SO 2 R 10 .
5. The compound of claim 3 , wherein A 2 is a heterocycloalkyl group containing at least one nitrogen or sulfur atom, and wherein said heterocycloalkyl group is substituted with one or more substituents independently selected from the group consisting of —CO 2 R 8 , —CON(R 8 )R 9 , —SO 2 N(R 8 )R 9 , and —SO 2 R 10 .
6. The compound of claim 3 , wherein A 2 is azetidinyl, pyrrolidinyl, or piperidinyl, each substituted with —CON(R 8 )R 9 , —CO 2 R 8 , —SO 2 N(R 8 )R 9 , or —SO 2 R 10 .
7. The compound of claim 3 , wherein A 2 is one of the following:
8. The compound of claim 1 , wherein R 2 is —O-heterocycloalkyl or —O—(CR 6 R 7 ) n —C 1 -C 6 alkoxyl; wherein said heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, —CO 2 R 8 , —CON(R 8 )R 9 , —SO 2 N(R 8 )R 9 , and —SO 2 R 10 .
9. The compound of claim 1 , wherein R 2 is —O-heterocycloalkyl; wherein said heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of —CO 2 R 8 , —CON(R 8 )R 9 , —SO 2 N(R 8 )R 9 , and —SO 2 R 10 .
10. The compound of claim 1 , wherein R 2 is morpholinyl, —O-tetrahydrofuranyl, O-tetrahydropyranyl, —O-pyrrolidinyl, O-azetidinyl or —O-piperidinyl; wherein said pyrrolidinyl, azetidinyl or piperidinyl each independently is optionally substituted with one or more substituents independently selected from the group consisting of —CO 2 R 8 , —CON(R 8 )R 9 , —SO 2 N(R 8 )R 9 , and —SO 2 R 10 .
11. The compound of claim 1 , wherein R 2 is —O-tetrahydrofuranyl.
12. The compound of claim 1 , wherein R 3 is hydrogen, halogen, —OCF 3 , —OCH 2 F, —CF 3 , C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl.
13. The compound of claim 1 , wherein R 8 and R 9 each represent independently for each occurrence hydrogen, methyl, ethyl or cyclopropyl.
14. The compound of claim 1 , wherein R 10 is methyl, ethyl, n-propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, phenyl, or benzyl.
15. The compound of claim 1 , wherein A 1 is phenylene.
16. The compound of claim 1 , wherein W is C 5 -C 10 cycloalkyl optionally substituted with one or two substituents independently selected from the group consisting of C 1 -C 6 alkyl, —CF 3 , and fluoro.
17. The compound of claim 1 , wherein W is cyclohexyl substituted with one or two substituents independently selected from the group consisting of C 1 -C 6 alkyl, —CF 3 , and fluoro.
18. The compound of claim 1 , wherein the compound is selected from the group consisting of: N,N-dimethyl-3-(2-((1s,4S)-4-methylcyclohexylamino)-5-(4-morpholinophenyl)pyrimidin-4-yloxy)azetidine-1-sulfonamide; N-(cis-4-methylcyclohexyl)-4-(1-(methylsulfonyl)azetidin-3-yloxy)-5-(4-((R)-tetrahydrofuran-3-yloxy)phenyl)pyrimidin-2-amine; N-(cis-4-methylcyclohexyl)-4-(1-(methylsulfonyl)azetidin-3-yloxy)-5-(4-((S)-tetrahydrofuran-3-yloxy)phenyl)pyrimidin-2-amine; methyl 4-(2-((1s,4s)-4-methylcyclohexylamino)-5-(4-morpholinophenyl)pyrimidin-4-yloxy)piperidine-1-carboxylate; N-((1s,4s)-4-methylcyclohexyl)-4-(1-(methylsulfonyl)piperidin-4-yloxy)-5-(4-((S)-tetrahydrofuran-3-yloxy)phenyl)pyrimidin-2-amine; N,N-dimethyl-3-(2-((1s,4s)-4-methylcyclohexylamino)-5-(4-((R)-tetrahydrofuran-3-yloxy)phenyl)pyrimidin-4-yloxy)azetidine-1-sulfonamide; N,N-dimethyl-3-(2-((1s,4s)-4-methylcyclohexylamino)-5-(4-((S)-tetrahydrofuran-3-yloxy)phenyl)pyrimidin-4-yloxy)azetidine-1-sulfonamide; and 4-(1-(cyclopropylsulfonyl)azetidin-3-yloxy)-N-((1s,4s)-4-methylcyclohexyl)-5-(4-((S)-tetrahydrofuran-3-yloxy)phenyl)pyrimidin-2-amine; or a pharmaceutically acceptable salt or N-oxide thereof.
19. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
20. A method of treating cystic fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .